11例伴t(14;19)(q32;q13)的慢性淋巴细胞白血病患者临床特征

OBJECTIVE: To analyze the clinicopathological characteristics of 11 cases of chronic lymphocytic leukemia（CLL）with t（14;19）（q32;q13）. METHODS: The case data of 11 patients with CLL with t（14;19）（q32;q13）in the chromosome karyotype analysis results of the Blood Diseases Hospital, Chinese Academy of Medical Sciences from January 1, 2018, to July 30, 2022, were retrospectively analyzed. RESULTS: In all 11 patients, t（14;19）（q32;q13）involved IGH::BCL3 gene rearrangement, and most of them were accompanied by +12 or complex karyotype. An immunophenotypic score of 4–5 was found in 7 patients and 3 in 4 cases. We demonstrated that CLLs with t（14;19）（q32;q13）had a mutational pattern with recurrent mutations in NOTCH1（3/7）, FBXW7（3/7）, and KMT2D（2/7）. The very-high-risk, high-risk, intermediate-risk, and low-risk groups consisted of 1, 1, 6, and 3 cases, respectively. Two patients died, 8 survived, and 2 were lost in follow-up. Four patients had disease progression or relapse during treatment. The median time to the first therapy was 1 month. CONCLUSION: t（14;19）（q32;q13）, involving IGH::BCL3 gene rearrangement, is a rare recurrent cytogenetic abnormality in CLL, which is associated with a poor prognosis.